![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supporting Information]](https://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supporting Information)
2MB |
| Item Type: | Article |
|---|---|
| Title: | Safety and efficacy of a sandwich total neoadjuvant therapy strategy for low-risk distal locally advanced rectal cancer: results from the TESS phase II trial |
| Creators: |
Liu, Shuang  ORCID: https://orcid.org/0000-0003-2347-413X, Lv, GuangZhao, Xu, GeYu, Wang, XiaoZhong, Zhuang, YeZhong, Bai, ShouMin, Yu, HaiNa, Wu, XiaoJun, Ye, YiJing, Luo, HuiLong, Xu, ShuoYu, Wang, QiaoXuan, Chang, Hui, Cai, PeiQiang, Pan, ZhiZhong, Gao, YuanHong, Chen, Gong and Xiao, WeiWei
|
| Abstract: | This prospective phase II multicenter study evaluated a novel sandwich total neoadjuvant treatment (TNT) strategy for patients with relatively low-risk distal locally advanced rectal cancer (LARC). The regimen consisted of two cycles of capecitabine and oxaliplatin (CapeOx) administrated before, during, and after radiotherapy, followed by surgery or a watch-and-wait strategy, and two cycles of adjuvant capecitabine chemotherapy. The primary endpoint was the clinical complete response (cCR) rate. All 98 patients completed radiotherapy, and 88.8% received six cycles of neoadjuvant chemotherapy. In the intention-to-treat analysis, 46.9% of patients achieved cCR, 7.1% achieved near-clinical complete response (near-cCR), and 45.9% had non-clinical complete response (non-cCR). In the observed population, the complete response (CR), pathological complete response (pCR), and sphincter-preservation (SP) rates were 61.2%, 46.4%, and 79.6%, respectively. The local regrowth-free survival, local recurrence-free survival, distant metastases-free survival, and overall survival rates were 89.5%, 100%, 92.9%, and 96.9%, respectively. Overall, this sandwich TNT strategy achieved high rates of cCR, pCR, CR, and SP, with favorable survival outcomes and acceptable toxicity, suggesting a promising organ-preserving treatment approach for selected patients with distal LARC. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03840239. |
| Keywords: | Rectal Cancer, Rectal Cancer, Sphincter Preservation, Total Neoadjuvant Treatment, Watch-and-Wait Strategy |
| Source: | MedComm |
| ISSN: | 2688-2663 |
| Publisher: | Wiley |
| Volume: | 7 |
| Number: | 7 |
| Page Range: | e70807 |
| Date: | July 2026 |
| Official Publication: | https://doi.org/10.1002/mco2.70807 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
